C A Labarrere

Summary

Affiliation: Clarian Health Partners
Country: USA

Publications

  1. doi Early prediction of cardiac allograft vasculopathy and heart transplant failure
    C A Labarrere
    Experimental Pathology, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN, USA
    Am J Transplant 11:528-35. 2011
  2. ncbi Microvascular thrombosis and cardiac allograft vasculopathy in rat heart transplantation
    Carlos A Labarrere
    Division of Experimental Pathology, Methodist Research Institute, Clarian Health Partners, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 25:1213-22. 2006
  3. ncbi Syncytiotrophoblast intercellular adhesion molecule-1 expression in placental villitis of unknown cause
    Carlos A Labarrere
    ImmunoPath, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN 46202, USA
    Am J Obstet Gynecol 193:483-8. 2005
  4. ncbi C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners, Inc, Indianapolis, Indiana 46202, USA
    Am J Med 117:499-507. 2004
  5. ncbi C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners, Methodist, Indiana University, Riley Hospitals, Indianapolis, IN 46202, USA
    Lancet 360:1462-7. 2002
  6. ncbi Microvascular prothrombogenicity and transplant coronary artery disease
    Carlos A Labarrere
    Methodist Research Institute at Clarian Health, Indianapolis, IN 46202, USA
    Transpl Immunol 9:243-9. 2002
  7. ncbi Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection
    C A Labarrere
    Methodist Research Institute, Clarian Health Partners, Methodist, Indiana University, Riley Hospitals, 1701 N Senate Blvd, Indianapolis, IN 46202, USA
    Curr Opin Cardiol 16:110-7. 2001
  8. ncbi Vascular antithrombin and clinical outcome in heart transplant patients
    C A Labarrere
    Methodist Research Institute, Methodist Transplant Center, Indiana University, Riley Hospitals, Indianapolis 46202, USA
    Am J Cardiol 87:425-31. 2001
  9. ncbi Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation
    C A Labarrere
    Methodist Research Institute, Clarian Health, 1812 N Capitol Ave, Indianapolis, IN 46202, USA
    JAMA 284:457-64. 2000
  10. ncbi Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules
    George Boguslawski
    Methodist Research Institute, Clarian Health Partners, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 26:705-13. 2007

Collaborators

Detail Information

Publications17

  1. doi Early prediction of cardiac allograft vasculopathy and heart transplant failure
    C A Labarrere
    Experimental Pathology, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN, USA
    Am J Transplant 11:528-35. 2011
    ..Early absence of atherothrombotic risk identifies a patient subgroup that rarely develops CAV or graft failure, implying that this low-risk subgroup could possibly be followed with fewer invasive procedures...
  2. ncbi Microvascular thrombosis and cardiac allograft vasculopathy in rat heart transplantation
    Carlos A Labarrere
    Division of Experimental Pathology, Methodist Research Institute, Clarian Health Partners, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 25:1213-22. 2006
    ..The aim of this study was to identify an animal model by which to further evaluate the role of coagulation in the pathogenesis of CAV...
  3. ncbi Syncytiotrophoblast intercellular adhesion molecule-1 expression in placental villitis of unknown cause
    Carlos A Labarrere
    ImmunoPath, Methodist Research Institute, Clarian Health Partners, Indianapolis, IN 46202, USA
    Am J Obstet Gynecol 193:483-8. 2005
    ..The purpose of this study was to determine syncytiotrophoblast intercellular adhesion molecule-1 expression in villitis and in normal chorionic villi from term (37-42 weeks of gestation) placentas with or without villitis...
  4. ncbi C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners, Inc, Indianapolis, Indiana 46202, USA
    Am J Med 117:499-507. 2004
    ..We also discuss the evidence that C-reactive protein can injure arterial endothelium. Finally, we review therapies that target C-reactive protein for primary prevention and for the treatment of atherosclerotic diseases...
  5. ncbi C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners, Methodist, Indiana University, Riley Hospitals, Indianapolis, IN 46202, USA
    Lancet 360:1462-7. 2002
    ..We investigated whether C-reactive protein, known to stimulate ICAM-1, was associated with increased ICAM-1 concentration and subsequent development of coronary artery disease...
  6. ncbi Microvascular prothrombogenicity and transplant coronary artery disease
    Carlos A Labarrere
    Methodist Research Institute at Clarian Health, Indianapolis, IN 46202, USA
    Transpl Immunol 9:243-9. 2002
    ..Reducing prothrombogenicity of the cardiac microvasculature early after transplantation could slow the development of transplant CAD and significantly improve allograft survival...
  7. ncbi Pathologic markers of allograft arteriopathy: insight into the pathophysiology of cardiac allograft chronic rejection
    C A Labarrere
    Methodist Research Institute, Clarian Health Partners, Methodist, Indiana University, Riley Hospitals, 1701 N Senate Blvd, Indianapolis, IN 46202, USA
    Curr Opin Cardiol 16:110-7. 2001
    ..New therapies that could improve the status of the allograft microvasculature and may prevent or mitigate the development of transplant-associated CAD are considered...
  8. ncbi Vascular antithrombin and clinical outcome in heart transplant patients
    C A Labarrere
    Methodist Research Institute, Methodist Transplant Center, Indiana University, Riley Hospitals, Indianapolis 46202, USA
    Am J Cardiol 87:425-31. 2001
    ..However, recovery of vascular antithrombin and development of unusual capillary antithrombin binding improves allograft outcome...
  9. ncbi Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation
    C A Labarrere
    Methodist Research Institute, Clarian Health, 1812 N Capitol Ave, Indianapolis, IN 46202, USA
    JAMA 284:457-64. 2000
    ..Previous studies have yielded conflicting data regarding whether a relationship exists between elevated cardiac troponin levels and acute allograft rejection in patients who have received heart transplants...
  10. ncbi Conduct unbecoming: C-reactive protein interactions with a broad range of protein molecules
    George Boguslawski
    Methodist Research Institute, Clarian Health Partners, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 26:705-13. 2007
    ..Understanding the biology of CRP may be relevant to understanding atherosclerosis development and progression...
  11. ncbi Non-immunologic vascular failure of the transplanted heart
    Carlos A Labarrere
    Methodist Research Institute, Clarian Health Partners Methodist, Indiana University and Riley Hospitals, Indianapolis, Indiana 46202, USA
    J Heart Lung Transplant 22:236-40. 2003
  12. doi Continuously-infused human C-reactive protein is neither proatherosclerotic nor proinflammatory in apolipoprotein E-deficient mice
    Miguel A Ortiz
    Methodist Research Institute, Clarian Health, 1800 N Capitol Avenue, Suite E504A, Indianapolis, IN 46202, USA
    Exp Biol Med (Maywood) 234:624-31. 2009
    ....
  13. pmc Precision of biomarkers to define chronic inflammation in CKD
    Robert LaClair
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Am J Nephrol 28:808-12. 2008
    ..The purpose of the present study was to determine the intrapatient variation of C-reactive protein, IL-6, fetuin-A and albumin in a population of dialysis patients...
  14. ncbi Expression of a novel high molecular-weight myosin light chain kinase in endothelium
    A D Verin
    Department of Medicine, Physiology and Biophysics, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Am J Respir Cell Mol Biol 19:758-66. 1998
    ..These data suggest that the novel 214-kD kinase, the only MLCK isoform found in endothelium, may be preferentially expressed in this nonmuscle tissue...
  15. pmc Suppressed hindlimb perfusion in Rac2-/- and Nox2-/- mice does not result from impaired collateral growth
    Matthew R Distasi
    Department of Cellular and Integrative Physiology, Indiana Univ School of Medicine, 1001 W 10th St, WD OPW 425 E, Indianapolis, IN 46202, USA
    Am J Physiol Heart Circ Physiol 296:H877-86. 2009
    ..These novel results indicate that collateral luminal expansion and intimal cell recruitment/proliferation are not mediated by Rac2 and Nox2...
  16. ncbi Development of progressive aortic vasculopathy in a rat model of aging
    Steven J Miller
    Department of Surgery, Indiana University School of Medicine, Indianapolis, IN 46202 2879, USA
    Am J Physiol Heart Circ Physiol 293:H2634-43. 2007
    ..The results demonstrate that major structural abnormalities and altered gene expression develop after 6 mo and that the progressive pathological development is associated with increased inflammation and oxidant stress...
  17. ncbi Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography
    Beate R Jaeger
    Institut fur Klinische Chemie, Klinikum der Universitat Munchen, Munchen, Germany
    J Heart Lung Transplant 24:2022-30. 2005
    ....